SEC Form 4 · accession 0001179110-17-000728
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert L. Martin
Officer — Sr. Vice President
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 7:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $1.82 | Jan 4, 2017 | A | 21,000 | A | Jan 4, 2017 | Jul 25, 2026 | Common Stock | 21,000 | 42,000 | D |
Explanation of responses
- F1On July 25, 2016, the Reporting Person was granted an option to purchase 42,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met on December 30, 2016, resulting in vesting of the option as to 21,000 shares, which was reported on a prior Form 4. The second milestone was met on January 4, 2017, resulting in vesting of the option as to the remaining 21,000 shares.